Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
10. August 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr...
Abeona Therapeutics Reports Second Quarter Financial Results
28. Juli 2021 16:01 ET
|
Abeona Therapeutics Inc.
Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study Successful Type B meeting with U.S. FDA; Transpher A study will serve as the pivotal study for ABO-102 in MPS IIIA;...
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
28. Juli 2021 07:30 ET
|
Abeona Therapeutics Inc.
Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease Alignment with FDA on primary study endpoint NEW YORK and CLEVELAND, July 28, 2021 (GLOBE NEWSWIRE) -- Abeona...
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
26. Juli 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene therapy, today announced magnetic resonance imaging (MRI) data...
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa
23. Juli 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second...
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting
07. Juli 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical...
Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference
02. Juni 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, President...
Abeona Therapeutics Issues Letter to Stockholders
26. Mai 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to...
Abeona Therapeutics Appoints Head of Research & Clinical Development
25. Mai 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Vishwas...
Abeona Therapeutics Reports First Quarter Financial Results
18. Mai 2021 07:30 ET
|
Abeona Therapeutics Inc.
Patient enrollment ongoing for EB-101 pivotal Phase 3 VIITAL™ study Positive interim MPS III data presented at 17th Annual WORLDSymposium; additional neurocognitive assessments of patients treated in...